2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
A. Oliver Sartor, MD, discusses the phase III VISION trial in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses the phase III VISION trial in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
The VISION trial recently completed its accrual of 815 patients, says Sartor. Patients will be randomized 2:1 to receive standard of care with or without the radiopharmaceutical, lutetium-177 PSMA-617 (LuPSMA). Overall survival and radiographic progression-free survival will serve as primary and secondary endpoints of the trial, respectively.
Positive results from the VISION trial could introduce an option for patients previously treated with androgen receptor inhibitors such as abiraterone acetate (Zytiga) or enzalutamide (Xtandi), and taxane chemotherapy. Currently, there is no approved treatment or standard of care in this space, concludes Sartor.